Lipid and protein oxidation in newborn infants after lutein administration

S Perrone, M Tei, M Longini, A Santacroce, G Turrisi, F Proietti, C Felici, A Picardi, F Bazzini, P Vasarri, G Buonocore, S Perrone, M Tei, M Longini, A Santacroce, G Turrisi, F Proietti, C Felici, A Picardi, F Bazzini, P Vasarri, G Buonocore

Abstract

Objectives: To test the hypothesis that neonatal supplementation with lutein in the first hours of life reduces neonatal oxidative stress (OS) in the immediate postpartum period.

Methods: A randomized controlled, double-blinded clinical trial was conducted among 150 newborns divided into control group, not supplemented (n = 47), and test group, supplemented with lutein on the first day postpartum (n = 103). Blood Samples were collected at birth from cord and at 48 hrs postpartum while routine neonatal metabolic screenings were taking place. Total hydroperoxide (TH), advanced oxidation protein products (AOPP), and biological antioxidant potential (BAP) were measured by spectrophotometry and data were analyzed by Wilcoxon rank sum test and by multivariate logistic regression analysis.

Results: Before lutein supplementation, the mean blood concentrations of AOPP, TH, and BAP were 36.10 umol/L, 156.75 mmol/H2O2, and 2361.04 umol/L in the test group. After lutein supplementation, significantly higher BAP increment (0.17 ± 0.22 versus 0.06 versus ± 0.46) and lower TH increment (0.46 ± 0.54 versus 0.34 ± 0.52) were observed in the test group compared to controls.

Conclusion: Neonatal supplementation with lutein in the first hours of life increases BAP and reduces TH in supplemented babies compared to those untreated. The generation of free radical-induced damage at birth is reduced by lutein. This trial is registered with ClinicalTrials.gov NCT02068807.

Figures

Figure 1
Figure 1
Plasma concentration of BAP in cord blood and at 48 hrs of life.
Figure 2
Figure 2
ROC curve for the multivariate logistic model (AUC = 81.3%, c.i. = 68.4%–94.3%).

References

    1. Ojima F, Sakamoto H, Ishiguro Y, Terao J. Consumption of carotenoids in photosensitized oxidation of human plasma and plasma low-density lipoprotein. Free Radical Biology and Medicine. 1993;15(4):377–384.
    1. Alves-Rodrigues A, Shao A. The science behind lutein. Toxicology Letters. 2004;150(1):57–83.
    1. Ribaya-Mercado JD, Blumberg JB. Lutein and zeaxanthin and their potential roles in disease prevention. Journal of the American College of Nutrition. 2004;23(6):567S–587S.
    1. Perrone S, Negro S, Tataranno ML, Buonocore G. Oxidative stress and antioxidant strategies in newborns. Journal of Maternal-Fetal and Neonatal Medicine. 2010;23(S3):63–65.
    1. Izumi-Nagai K, Nagai N, Ohgami K, et al. Macular pigment lutein is antiinflammatory in preventing choroidal neovascularization. Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27(12):2555–2562.
    1. Sasaki M, Ozawa Y, Kurihara T, et al. Neuroprotective effect of an antioxidant, lutein, during retinal inflammation. Investigative Ophthalmology and Visual Science. 2009;50(3):1433–1439.
    1. Kim SR, Nakanishi K, Itagaki Y, Sparrow JR. Photooxidation of A2-PE, a photoreceptor outer segment fluorophore, and protection by lutein and zeaxanthin. Experimental Eye Research. 2006;82(5):828–839.
    1. Chucair AJ, Rotstein NP, SanGiovanni JP, During A, Chew EY, Politi LE. Lutein and zeaxanthin protect photoreceptors from apoptosis induced by oxidative stress: relation with docosahexaenoic acid. Investigative Ophthalmology and Visual Science. 2007;48(11):5168–5177.
    1. Kim JE, Leite JO, deOgburn R, Smyth JA, Clark RM, Fernandez ML. A Lutein-enriched diet prevents cholesterol accumulation and decreases oxidized LDL and inflammatory cytokines in the aorta of guinea pigs. Journal of Nutrition. 2011;141(8):1458–1463.
    1. Kim J-H, Na H-J, Kim C-K, et al. The non-provitamin A carotenoid, lutein, inhibits NF-κB-dependent gene expression through redox-based regulation of the phosphatidylinositol 3-kinase/PTEN/Akt and NF-κB-inducing kinase pathways: role of H2O2 in NF-κB activation. Free Radical Biology and Medicine. 2008;45(6):885–896.
    1. O’Neill ME, Carroll Y, Corridan B, et al. A European carotenoid database to assess carotenoid intakes and its use in a five-country comparative study. British Journal of Nutrition. 2001;85(4):499–507.
    1. Mangels AR, Holden JM, Beecher GR, Forman MR, Lanza E. Carotenoid content of fruits and vegetables: an evaluation of analytic data. Journal of the American Dietetic Association. 1993;93:284–296.
    1. Sommerburg O, Keunen JEE, Bird AC, Van Kuijk FJGM. Fruits and vegetables that are sources for lutein and zeaxanthin: the macular pigment in human eyes. British Journal of Ophthalmology. 1998;82(8):907–910.
    1. Bettler J, Zimmer JP, Neuringer M, Derusso PA. Serum lutein concentrations in healthy term infants fed human milk or infant formula with lutein. European Journal of Nutrition. 2010;49(1):45–51.
    1. Tacken KJM, Vogelsang A, Van Lingen RA, Slootstra J, Dikkeschei BD, Van Zoeren-Grobben D. Loss of triglycerides and carotenoids in human milk after processing. Archives of Disease in Childhood: Fetal and Neonatal Edition. 2009;94(6):F447–F450.
    1. Manzoni P, Guardione R, Bonetti P, et al. Lutein and zeaxanthin supplementation in preterm very low-birth-weight neonates in neonatal intensive care units: a multicenter randomized controlled trial. The American Journal of Perinatology. 2013;30(1):25–32.
    1. Dani C, Lori I, Favelli F, et al. Lutein and zeaxanthin supplementation in preterm infants to prevent retinopathy of prematurity: a randomized controlled study. Journal of Maternal-Fetal and Neonatal Medicine. 2012;25(5):523–527.
    1. Romagnoli C, Giannantonio C, Cota F, et al. A prospective, randomized, double blind study comparing lutein to placebo for reducing occurrence and severity of retinopathy of prematurity. Journal of Maternal-Fetal and Neonatal Medicine. 2011;24(S1):147–150.
    1. Rubin LP, Chan GM, Barrett-Reis BM, et al. Effect of carotenoid supplementation on plasma carotenoids, inflammation and visual development in preterm infants. Journal of Perinatology. 2012;32(6):418–424.
    1. Perrone S, Longini M, Marzocchi B, et al. Effects of lutein on oxidative stress in the term newborn: a pilot study. Neonatology. 2009;97(1):36–40.
    1. Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney International. 1996;49(5):1304–1313.
    1. Benzie IFF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Analytical Biochemistry. 1996;239(1):70–76.
    1. Buonocore G, Perrone S, Longini M, Terzuoli L, Bracci R. Total hydroperoxide and advanced oxidation protein products in preterm hypoxic babies. Pediatric Research. 2000;47(2):221–224.
    1. Myles H, Douglas AW. Nonparametric Statistical Methods. New York, NY, USA: John Wiley & Sons; 1973.
    1. Venables WN, Ripley BD. Modern Applied Statistics. New York, NY, USA: Springer; 2002.
    1. Akaike H. A new look at the statistical model identification. IEEE Transactions on Automatic Control. 1974;AC-19(6):716–723.
    1. Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: visualizing classifier performance in R. Bioinformatics. 2005;21(20):3940–3941.
    1. Chambers JM, Cleveland WS, Kleiner B, et al. Graphical Methods For Data Analysis. Wadsworth & Brooks/Cole. Duxbury Press; 1983.
    1. Frank L, Sosenko IRS. Prenatal development of lung antioxidant enzymes in four species. Journal of Pediatrics. 1987;110(1):106–110.
    1. Buonocore G, Perrone S, Longini M, et al. Oxidative stress in preterm neonates at birth and on the seventh day of life. Pediatric Research. 2002;52(1):46–49.
    1. Perrone S, Tataranno LM, Stazzoni G, et al. Brain susceptibility to oxidative stress in the perinatal period. Journal of Maternal-Fetal and Neonatal Medicine. 2013
    1. Ozawa Y, Sasaki M, Takahashi N, Kamoshita M, Miyake S, Tsubota K. Neuroprotective effects of lutein in the retina. Current Pharmaceutical Design. 2012;18(1):51–56.
    1. Woodall AA, Britton G, Jackson MJ. Carotenoids and protection of phospholipids in solution or in liposomes against oxidation by peroxyl radicals: relationship between carotenoid structure and protective ability. Biochimica et Biophysica Acta. 1997;1336(3):575–586.
    1. Roberts RL, Green J, Lewis B. Lutein and zeaxanthin in eye and skin health. Clinics in Dermatology. 2009;27(2):195–201.
    1. Costa S, Giannantonio C, Romagnoli C, et al. Effects of lutein supplementation on biological antioxidant status in preterm infants: a randomized clinical trial. Journal of Maternal-Fetal and Neonatal Medicine. 2013;26(13):1311–1315.
    1. Li SY, Fung FK, Fu ZJ, et al. Anti-inflammatory effects of lutein in retinal ischemic/hypoxic injury: in vivo and in vitro studies. Investigative Ophthalmology & Visual Science. 2012;53(10):5976–5984.
    1. Song HS, Kim HR, Kim MC, Hwang YH, Sim SS. Lutein is a competitive inhibitor of cytosolic Ca2+-dependent phospholipase A2 . Journal of Pharmacy and Pharmacology. 2010;62(12):1711–1716.
    1. Oh J, Kim JH, Park JG, et al. Radical scavenging activity-based and AP-1-targeted anti-inflammatory effects of lutein in macrophage-like and skin keratinocytic cells. Mediators of Inflammation. 2013;2013:8 pages.787042
    1. Kim Y, Seo JH, Kim H. β-Carotene and lutein inhibit hydrogen peroxide-induced activation of NF-κB and IL-8 expression in gastric epithelial AGS cells. Journal of Nutritional Science and Vitaminology. 2011;57(3):216–223.
    1. Bian Q, Qin T, Ren Z, Wu D, Shang F. Lutein or zeaxanthin supplementation suppresses inflammatory responses in retinal pigment epithelial cells and macrophages. Advances in Experimental Medicine and Biology. 2012;723:43–50.
    1. Gao S, Qin T, Liu Z, et al. Lutein and zeaxanthin supplementation reduces H2O2-induced oxidative damage in human lens epithelial cells. Molecular Vision. 2011;17:3180–3190.
    1. Ravikrishnan R, Rusia S, Ilamurugan G, et al. Safety assessment of lutein and zeaxanthin (Lutemax 2020): subchronic toxicity and mutagenicity studies. Food and Chemical Toxicology. 2011;49(11):2841–2848.
    1. GRAS Notice No. GNR, 000140 issued by CFSAN/Office of Food Additive Safety, .

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel